Stocks To Buy Now

Blog


On the Move Systems (OMVS) Sees Opportunity to Fuel Additional Trucking Industry Growth

On the Move Systems’ (OMVS) upcoming “Uber-for-Trucking” on-demand platform is expected to do well, especially since the nation’s trucking industry is currently in the midst of an impressive growth spurt. The company’s platform will offer freight haulers a cutting-edge technology based solution to encourage continued growth.

The American Trucking Associations (ATA) recently published its U.S. Freight Transportation Forecast, which boldly predicted the industry will enjoy a robust 29 percent increase in freight volumes by 2026. “The outlook for all modes of freight transportation remains bright,” said ATA Chief Economist Bob Costello. “Continued population growth, expansion of the energy sector and foreign trade will boost trucking, intermodal rail and pipeline shipments.”

While the industry outlook appears stunningly bright, there is one potential dark cloud on the horizon: a continuing driver shortage. Reports estimate trucking companies currently face a shortage of 35,000 drivers.

“These two news items definitely indicate a real opportunity for a technology solutions company like ours,” stated OMVS CEO Robert Wilson. “The predicted freight volume increase should drive demand for our shared economy platform, as firms will want to optimize these additional loads and routes. However, they’ll need drivers to haul these additional loads and our app can help there as well in connecting companies with local independent drivers wanting to contract with carriers. Our innovative platform looks like it will debut at a very opportune time.”

A recent industry outlook from Frost & Sullivan predicted trucking will soon see an Uber-style transformation, where shared economy platforms and apps, like the one now under development by OMVS, will play a major role in operations and revenue-generation.

For more information, visit www.onthemovesystems.com

Let us hear your thoughts: On the Move Systems Corp. Message Board

From Our Blog

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

March 31, 2026

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing […]

Rotate your device 90° to view site.